Document Detail


Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide.
MedLine Citation:
PMID:  20610873     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Nitric oxide (NO) plays an important role in inhibiting the development of hepatic fibrosis and its ensuing complication of portal hypertension by inhibiting human hepatic stellate cell (HSC) activation. Here we have developed a gold nanoparticle and silica nanoparticle mediated drug delivery system containing NO donors, which could be used for potential therapeutic application in chronic liver disease. The gold nanoconjugates were characterized using several physico-chemical techniques such as UV-visible spectroscopy and transmission electron microscopy. Silica nanoconjugates were synthesized and characterized as reported previously. NO released from gold and silica nanoconjugates was quantified under physiological conditions (pH = 7.4 at 37 degrees C) for a substantial period of time. HSC proliferation and the vascular tube formation ability, manifestations of their activation, were significantly attenuated by the NO released from these nanoconjugates. This study indicates that gold and silica nanoparticle mediated drug delivery systems for introducing NO could be used as a strategy for the treatment of hepatic fibrosis or chronic liver diseases, by limiting HSC activation.
Authors:
Amitava Das; Priyabrata Mukherjee; Sumit K Singla; Praveen Guturu; Megan C Frost; Debabrata Mukhopadhyay; Vijay H Shah; Chitta Ranjan Patra
Related Documents :
21627343 - Temsirolimus in relapsed and/or refractory mantle cell lymphoma†: profile report.
20205603 - Triggered drug delivery from biomaterials.
12019133 - In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides again...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-07-08
Journal Detail:
Title:  Nanotechnology     Volume:  21     ISSN:  1361-6528     ISO Abbreviation:  Nanotechnology     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-28     Completed Date:  2011-02-15     Revised Date:  2012-05-17    
Medline Journal Info:
Nlm Unique ID:  101241272     Medline TA:  Nanotechnology     Country:  England    
Other Details:
Languages:  eng     Pagination:  305102     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Proliferation / drug effects
Drug Delivery Systems / methods*
Endocytosis / drug effects
Gold / chemistry*
Hepatic Stellate Cells / cytology,  drug effects,  metabolism,  ultrastructure
Humans
Kinetics
Metal Nanoparticles / chemistry*,  ultrastructure
Nanomedicine / methods
Neovascularization, Physiologic / drug effects
Nitric Oxide / administration & dosage*
Nitric Oxide Donors / pharmacology
Phenotype
S-Nitroso-N-Acetylpenicillamine / pharmacology
Silicon Dioxide / chemistry*
Spectrophotometry, Ultraviolet
Grant Support
ID/Acronym/Agency:
P30 DK 084567/DK/NIDDK NIH HHS; R01 DK 59615/DK/NIDDK NIH HHS; R01 DK059615/DK/NIDDK NIH HHS; R01 DK059615-09/DK/NIDDK NIH HHS; R01 HL 86990/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Nitric Oxide Donors; 10102-43-9/Nitric Oxide; 7440-57-5/Gold; 7631-86-9/Silicon Dioxide; 79032-48-7/S-Nitroso-N-Acetylpenicillamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New insights into the use of magnetic force microscopy to discriminate between magnetic and nonmagne...
Next Document:  Effect of chondroitin sulfate-E on the osteoclastic differentiation of RAW264 cells.